Akcea Therapeutics

Akcea Therapeutics is a late-stage biopharmaceutical company developing drugs for the treatment of cardiometabolic diseases caused by lipid disorders. It focuses on four drugs: Volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx, that are based on antisense technology.

Employee Rating

2.9More
TypeSubsidiary
Parent CompanyIonis Pharmaceuticals
HQBoston, MA, US
Founded2014
Websiteakceatx.com
Cybersecurity ratingAMore
Akcea Therapeutics was founded in 2014 and is headquartered in Boston, MA, US

Viewing summary data as a guest

Sign up for free to see all data
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Akcea Therapeutics

Ian MacPherson

Ian MacPherson

Chief of Staff
Duncan Brown

Duncan Brown

Director, Health Economics & Outcomes Research
Cory Varney

Cory Varney

Director, Channel Operations, GP, and Payer Analytics
Louis St. L. O'Dea

Louis St. L. O'Dea

Strategic Advisor
Show more

Akcea Therapeutics Office Locations

Akcea Therapeutics has offices in Boston and Cambridge
Boston, MA, US (HQ)
22 Boston Wharf Rd 7th Floor
Cambridge, MA, US
55 Cambridge Pkwy #100
Show all (2)

Akcea Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2014
Akcea Therapeutics is a subsidiary of Ionis Pharmaceuticals

Akcea Therapeutics Revenue

USDFY, 2014FY, 2015FY, 2016

General and administrative expense

995.0k10.6m15.1m

R&D expense

29.0m50.9m68.5m

Operating expense total

30.0m61.4m83.5m
USDFY, 2015FY, 2016

Cash

29.4m7.9m

Current Assets

64.5m9.1m

PP&E

10.0k177.0k

Total Assets

66.1m10.7m
USDFY, 2014FY, 2015FY, 2016

Net Income

(30.0m)(61.4m)(83.2m)

Depreciation and Amortization

119.0k137.0k301.0k

Accounts Payable

9.4m15.1m

Cash From Operating Activities

(29.9m)(44.3m)(55.4m)
Show all financial metrics

Akcea Therapeutics Operating Metrics

Jun, 2017

Approval Phase Products

1

Phase I Trials Products

2

Phase II Trials Products

1

Phase III Trials Products

1
Show all operating metrics

Akcea Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Akcea Therapeutics Online and Social Media Presence

Embed Graph

Akcea Therapeutics News and Updates

Kaskela Law LLC Announces Stockholder Investigation of Akcea Therapeutics, Inc. (AKCA) and Encourages Investors to Contact the Firm

PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Akcea Therapeutics, Inc. ("Akcea") (NASDAQ: AKCA) on behalf of the company's shareholders. On August 31, 2020, Akcea announced that it had entered into an agreement to be acquired by Ionis...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Akcea Therapeutics, Inc.

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akcea Therapeutics, Inc. ("AKCA" or the "Company") (NASDAQ: AKCA) in connection with the proposed interested-party acquisition...

Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics

CARLSBAD, Calif. and BOSTON, Aug. 31, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares...

Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast

BOSTON, July 21, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2020 financial results and...

Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team

BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Lisa Johnson-Pratt, M.D., has joined the company as senior vice president of new product strategy. In this role, Dr. Johnson-Pratt wil…

Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference

BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, Interim CEO, will pre…
Show more

Akcea Therapeutics Frequently Asked Questions

  • When was Akcea Therapeutics founded?

    Akcea Therapeutics was founded in 2014.

  • Who are Akcea Therapeutics key executives?

    Akcea Therapeutics's key executives are Ian MacPherson, Duncan Brown and Cory Varney.

  • How many employees does Akcea Therapeutics have?

    Akcea Therapeutics has 100 employees.

  • Who are Akcea Therapeutics competitors?

    Competitors of Akcea Therapeutics include Biocon, Biogen and CSL Behring.

  • Where is Akcea Therapeutics headquarters?

    Akcea Therapeutics headquarters is located at 22 Boston Wharf Rd 7th Floor, Boston.

  • Where are Akcea Therapeutics offices?

    Akcea Therapeutics has offices in Boston and Cambridge.

  • How many offices does Akcea Therapeutics have?

    Akcea Therapeutics has 2 offices.